AZ/Merck & Co’s Lynparza sets ‘new standards’ in ovarian cancerAstraZeneca and Merck & Co’s Lynparza should be the standard therapy for a certain group of ovarian cancer patients according to US Share XAZ/Merck & Co’s Lynparza sets ‘new standards’ in ovarian cancerhttps://pharmaphorum.com/news/azs-lynparza-sets-new-standards-in-ovarian-cancer-say-experts/
AZ/Merck & Co’s ovarian cancer drug gets wider US licenceAstraZeneca and Merck & Co have hit back at their rival GlaxoSmithKline after the FDA allowed Lynparza to Share XAZ/Merck & Co’s ovarian cancer drug gets wider US licencehttps://pharmaphorum.com/news/az-merck-co-ovarian-cancer-drug-gets-wider-us-licence/
GSK takes fight to AZ/Merck & Co with first-line ovarian cancer approvalThe FDA has approved GlaxoSmithKline’s Zejula as first-line maintenance treatment for women with platinum-responsive ovarian cancer, competing against Share XGSK takes fight to AZ/Merck & Co with first-line ovarian cancer approvalhttps://pharmaphorum.com/news/fda-approves-gsks-zejula/
Epsilogen licenses first-in-class IgE ovarian cancer drugUK biotech Epsilogen has licensed rights to a drug for solid tumours developed by Kings College London and Share XEpsilogen licenses first-in-class IgE ovarian cancer drughttps://pharmaphorum.com/news/epsilogen-licenses-first-in-class-ige-ovarian-cancer-drug/
AZ’s cediranib falls short again in ovarian cancer combinationAstraZeneca and Merck & Co’s latest attempt to revive an old pipeline drug cediranib has failed as it Share XAZ’s cediranib falls short again in ovarian cancer combinationhttps://pharmaphorum.com/news/azs-cediranib-falls-short-again-in-ovarian-cancer-combination/
NICE rejects Astellas’ Xospata in AML, queries MSD’s Keytruda evidence in HNSCCNICE has been busy with announcements today, rejecting Astellas’ Xospata for a certain type of acute myeloid leukaemia Share XNICE rejects Astellas’ Xospata in AML, queries MSD’s Keytruda evidence in HNSCChttps://pharmaphorum.com/news/nice-rejects-astellas-xospata/
Transgene starts trials of ‘digital’ cancer vaccine with NECUndeterred by two clinical failures for its cancer immunotherapies in 2019, Transgene has kicked off the New Year Share XTransgene starts trials of ‘digital’ cancer vaccine with NEChttps://pharmaphorum.com/news/transgene-starts-trials-of-digital-cancer-vaccine-with-nec/
Scotland backs AZ’s Lynparza for first-line ovarian cancer maintenanceThe Scottish Medicines Consortium (SMC) has backed routine funding of AstraZeneca and MSD’s Lynparza as a maintenance treatment Share XScotland backs AZ’s Lynparza for first-line ovarian cancer maintenancehttps://pharmaphorum.com/news/scotland-backs-azs-lynparza-for-first-line-ovarian-cancer-maintenance/
NICE backs Lynparza across the board for BRCA+ovarian cancerAstraZeneca and MSD’s Lynparza has become the first PARP inhibitor to be recommended for all lines of maintenance Share XNICE backs Lynparza across the board for BRCA+ovarian cancerhttps://pharmaphorum.com/news/nice-backs-lynparza-across-the-board-for-brca-ovarian-cancer/
